Cochlear implant coverage
This article was originally published in The Gray Sheet
Executive Summary
CMS accepts Cochlear Corp. (Nucleus 24 contour implant system) request July 8 for consideration of expanded cochlear implant national coverage based on the firm's expanded labeling, granted by FDA in 2000. FDA allows implantation in patients with test scores of 50% or less, but CMS currently permits coverage for patients with demonstrated test scores of 30% or less. CMS requests that the public submit medical evidence and published literature detailing expanded use of cochlear implants in adults and children, patient selection criteria and the appropriate screening needed to qualify a patient for an implant. The agency expects to issue a decision by April 4, 2005...
You may also be interested in...
CMS Hears Earful From Supporters Of Cochlear Coverage Criteria Expansion
Advanced Bionics recommends that CMS tie coverage criteria for cochlear implants to FDA indications as an alternative to establishing specific cutoff criteria
UK Medtech Strategy Sets Out Schedule Of Milestones To FY 2026
Fourteen months on from the release of its inaugural medtech strategy, the UK MedTech Directorate has laid firm foundations and reports progress on initiatives aimed at improving technology adoption. A schedule of ambitious future timelines has also been published.
Chinese Firms Up Their Game In Novel Flu Antiviral Development
Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.